Global Chronic Obstructive Pulmonary Disorder (COPD) Market Research Report 2019

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Chronic Obstructive Pulmonary Disorder (COPD) Revenue
• 1.4 Market by Type
  • 1.4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Short-Acting Bronchodilators
  • 1.4.3 Corticosteroids
  • 1.4.4 Methylxanthines
  • 1.4.5 Long-Acting Bronchodilators
  • 1.4.6 Phosphodiesterase-4 Inhibitors
  • 1.4.7 Others
• 1.5 Market by Application
  • 1.5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Perspective (2015-2026)
• 2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Growth Trends by Regions
  • 2.2.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Share by Regions (2015-2020)
  • 2.2.3 Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Chronic Obstructive Pulmonary Disorder (COPD) Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Chronic Obstructive Pulmonary Disorder (COPD) Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Market Size
  • 3.1.1 Global Top Chronic Obstructive Pulmonary Disorder (COPD) Players by Revenue (2015-2020)
  • 3.1.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio
  • 3.2.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Chronic Obstructive Pulmonary Disorder (COPD) Revenue in 2019
• 3.3 Chronic Obstructive Pulmonary Disorder (COPD) Key Players Head office and Area Served
• 3.4 Key Players Chronic Obstructive Pulmonary Disorder (COPD) Product Solution and Service
• 3.5 Date of Enter into Chronic Obstructive Pulmonary Disorder (COPD) Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Historic Market Size by Type (2015-2020)
• 4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)
• 5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 6.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in North America (2019-2020)
• 6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 6.4 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 7.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Europe (2019-2020)
• 7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 7.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

8 China

• 8.1 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 8.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in China (2019-2020)
• 8.3 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 8.4 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 9.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Japan (2019-2020)
• 9.3 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 9.4 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 10.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 10.4 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

11 India

• 11.1 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 11.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in India (2019-2020)
• 11.3 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 11.4 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size (2015-2020)
• 12.2 Chronic Obstructive Pulmonary Disorder (COPD) Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type (2015-2020)
• 12.4 Central & South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 GSK
  • 13.1.1 GSK Company Details
  • 13.1.2 GSK Business Overview
  • 13.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.1.4 GSK Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020))
  • 13.1.5 GSK Recent Development
• 13.2 Pfizer
  • 13.2.1 Pfizer Company Details
  • 13.2.2 Pfizer Business Overview
  • 13.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.2.4 Pfizer Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.2.5 Pfizer Recent Development
• 13.3 Merck
  • 13.3.1 Merck Company Details
  • 13.3.2 Merck Business Overview
  • 13.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.3.4 Merck Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.3.5 Merck Recent Development
• 13.4 Novartis
  • 13.4.1 Novartis Company Details
  • 13.4.2 Novartis Business Overview
  • 13.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.4.4 Novartis Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.4.5 Novartis Recent Development
• 13.5 AstraZeneca
  • 13.5.1 AstraZeneca Company Details
  • 13.5.2 AstraZeneca Business Overview
  • 13.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.5.4 AstraZeneca Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.5.5 AstraZeneca Recent Development
• 13.6 Boehringer Ingelheim
  • 13.6.1 Boehringer Ingelheim Company Details
  • 13.6.2 Boehringer Ingelheim Business Overview
  • 13.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.6.4 Boehringer Ingelheim Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.6.5 Boehringer Ingelheim Recent Development
• 13.7 Teva Pharmaceuticals
  • 13.7.1 Teva Pharmaceuticals Company Details
  • 13.7.2 Teva Pharmaceuticals Business Overview
  • 13.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.7.4 Teva Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.7.5 Teva Pharmaceuticals Recent Development
• 13.8 Ario Pharma
  • 13.8.1 Ario Pharma Company Details
  • 13.8.2 Ario Pharma Business Overview
  • 13.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.8.4 Ario Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.8.5 Ario Pharma Recent Development
• 13.9 Roche
  • 13.9.1 Roche Company Details
  • 13.9.2 Roche Business Overview
  • 13.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.9.4 Roche Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.9.5 Roche Recent Development
• 13.10 Ache
  • 13.10.1 Ache Company Details
  • 13.10.2 Ache Business Overview
  • 13.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 13.10.4 Ache Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 13.10.5 Ache Recent Development
• 13.11 Almirall
  • 10.11.1 Almirall Company Details
  • 10.11.2 Almirall Business Overview
  • 10.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 10.11.4 Almirall Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 10.11.5 Almirall Recent Development
• 13.12 Aquinox Pharmaceuticals
  • 10.12.1 Aquinox Pharmaceuticals Company Details
  • 10.12.2 Aquinox Pharmaceuticals Business Overview
  • 10.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 10.12.4 Aquinox Pharmaceuticals Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 10.12.5 Aquinox Pharmaceuticals Recent Development
• 13.13 Asmacure
  • 10.13.1 Asmacure Company Details
  • 10.13.2 Asmacure Business Overview
  • 10.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 10.13.4 Asmacure Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 10.13.5 Asmacure Recent Development
• 13.14 Astellas Pharma
  • 10.14.1 Astellas Pharma Company Details
  • 10.14.2 Astellas Pharma Business Overview
  • 10.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Introduction
  • 10.14.4 Astellas Pharma Revenue in Chronic Obstructive Pulmonary Disorder (COPD) Business (2015-2020)
  • 10.14.5 Astellas Pharma Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer